GAUSH MEDITECH (02407) announced that its subsidiary, Gaush Innovation Technology Co., Ltd. (Gaush Innovation), has recently obtained a medical device registration certificate for its "Frequency Domain Biometer" approved by the Jiangsu Provincial Drug Administration.
According to the "China Eye Health White Paper" published by the National Health Commission in 2023, the overall myopia rate among Chinese adolescents is approximately 53.6%. With the continuous expansion of the myopic population, the market demand for myopia prevention and control is rapidly increasing. The "Research White Paper on China's Eyeglass Lens Industry" published by Sullivan indicates that China's myopia prevention and control market has been growing continuously in recent years, with acceleration beginning after 2022. The market size reached RMB 14.68 billion in 2023, representing a year-on-year growth of 43.2%.
Biometers are key equipment for myopia prevention and control, capable of performing micrometer-level precise measurements of axial length, corneal curvature, lens thickness, and other parameters. They play an important role in monitoring myopia progression in adolescents and evaluating the effectiveness of myopia prevention and control methods. They are also essential equipment for precise preoperative assessment in myopia refractive surgery.
The frequency domain biometer approved by Gaush Innovation (registration certificate number: Su Xie Zhu Zhun 20252161508) is developed based on the new generation frequency domain measurement principle. Compared to most traditional biometer products based on time domain principles, the frequency domain measurement principle offers higher resolution, faster imaging speed, and better signal-to-noise ratio.
The device also adopts an innovative dual optical path design (patent number: CN118526152A). When measuring eye parameters, it can perform real-time cross-sectional imaging of the patient's cornea, retina, and choroid, thereby assisting doctors in screening for myopia complications during myopia follow-up.
The device was independently developed by Gaush Innovation over two years and has achieved 100% domestic production of key optical, mechanical, and electrical components.